Where Will ATAI Life Sciences NV (ATAI) Stock Go Next After It Is Up 12.88% in a Week?

The market has been high on ATAI Life Sciences NV (ATAI) stock recently. ATAI gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

ATAI Life Sciences NV has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ATAI!

See Full ATAI Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With ATAI Stock Today?

ATAI Life Sciences NV (ATAI) stock has fallen -6.85% while the S&P 500 has risen 0.01% as of 10:02 AM on Monday, Apr 1. ATAI is lower by -$0.13 from the previous closing price of $1.97 on volume of 520,408 shares. Over the past year the S&P 500 is higher by 27.40% while ATAI is lower by -3.16%. ATAI lost -$0.25 per share in the over the last 12 months.

More About ATAI Life Sciences NV

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany. Click Here to get the full Stock Report for ATAI Life Sciences NV stock.